[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Thalidomide.]
[G03XB02, ulipristal, Ulipristal may increase the thrombogenic activities of Thalidomide.]
[B01AD01, streptokinase, The risk or severity of adverse effects can be increased when Streptokinase is combined with Thalidomide.]
[L01AD04, streptozocin, The risk or severity of adverse effects can be increased when Streptozocin is combined with Thalidomide.]
[L04AA27, fingolimod, Thalidomide may increase the immunosuppressive activities of Fingolimod.]
[M03AB01, succinylcholine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[J01EC02, sulfadiazine, The metabolism of Thalidomide can be decreased when combined with Sulfadiazine.]
[S01AB01, sulfamethizole, The metabolism of Thalidomide can be decreased when combined with Sulfamethizole.]
[J01EC01, sulfamethoxazole, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Thalidomide.]
[J01EC03, sulfamoxole, The metabolism of Thalidomide can be decreased when combined with Sulfamoxole.]
[J01EB04, sulfapyridine, The metabolism of Thalidomide can be decreased when combined with Sulfapyridine.]
[M04AB02, sulfinpyrazone, The metabolism of Thalidomide can be decreased when combined with Sulfinpyrazone.]
[S01AB02, sulfisoxazole, The metabolism of Thalidomide can be decreased when combined with Sulfisoxazole.]
[N05AL01, sulpiride, Sulpiride may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N03AX03, sulthiame, Sulthiame may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[A10BB04, glibornuride, The metabolism of Glibornuride can be decreased when combined with Thalidomide.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Thalidomide.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be increased when combined with Thalidomide.]
[N05CD07, temazepam, Temazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L01CB02, teniposide, The risk or severity of adverse effects can be increased when Teniposide is combined with Thalidomide.]
[B01AE07, dabigatran etexilate, The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Thalidomide.]
[G03BA03, testosterone, The metabolism of Testosterone can be increased when combined with Thalidomide.]
[S01HA03, tetracaine, Tetracaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05AE05, lurasidone, Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N04BC07, apomorphine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Thalidomide.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Thalidomide is combined with Antilymphocyte immunoglobulin (horse).]
[L01XX41, eribulin, The risk or severity of adverse effects can be increased when Thalidomide is combined with Eribulin.]
[R06AD03, thiethylperazine, Thiethylperazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L01AC01, thiotepa, The risk or severity of adverse effects can be increased when Thalidomide is combined with Thiotepa.]
[L01BB03, thioguanine, The risk or severity of adverse effects can be increased when Tioguanine is combined with Thalidomide.]
[N05CA19, thiopental, Thiopental may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05AB08, thioproperazine, Thioproperazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05AC02, thioridazine, Thioridazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05AF04, thiothixene, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05AL03, tiapride, Tiapride may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[B01AC05, ticlopidine, The risk or severity of bleeding can be increased when Ticlopidine is combined with Thalidomide.]
[N02AX01, tilidine, Tilidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[S01ED01, timolol, The risk or severity of adverse effects can be increased when Timolol is combined with Thalidomide.]
[A10BB05, tolazamide, The metabolism of Thalidomide can be decreased when combined with Tolazamide.]
[M02AX02, tolazoline, The risk or severity of adverse effects can be increased when Tolazoline is combined with Thalidomide.]
[V04CA01, tolbutamide, The metabolism of Tolbutamide can be decreased when combined with Thalidomide.]
[M03BX04, tolperisone, Tolperisone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N02AX02, tramadol, Tramadol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C01DX11, trapidil, The risk or severity of bleeding can be increased when Trapidil is combined with Thalidomide.]
[N06AX05, trazodone, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Tretinoin is combined with Thalidomide.]
[S01BA05, triamcinolone, The risk or severity of adverse effects can be increased when Triamcinolone is combined with Thalidomide.]
[C03DB02, triamterene, The risk or severity of adverse effects can be increased when Triamterene is combined with Thalidomide.]
[N05CD05, triazolam, Triazolam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C03AA06, trichlormethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Thalidomide.]
[A03AB12, mepenzolate, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[N05AB06, trifluoperazine, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[S01AD02, trifluridine, The risk or severity of adverse effects can be increased when Trifluridine is combined with Thalidomide.]
[N05AD02, trifluperidol, Trifluperidol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05AA05, triflupromazine, Triflupromazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[D07AC02, fluclorolone, The risk or severity of adverse effects can be increased when Thalidomide is combined with Fluclorolone.]
[N04AA01, trihexyphenidyl, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[R03BA07, mometasone, The risk or severity of adverse effects can be increased when Mometasone is combined with Thalidomide.]
[A03AA05, trimebutine, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AD01, trimeprazine, Alimemazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N03AC02, trimethadione, Trimethadione may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C02BA01, trimethaphan, Thalidomide may increase the hypotensive activities of Trimethaphan.]
[J01EA01, trimethoprim, The metabolism of Thalidomide can be decreased when combined with Trimethoprim.]
[N06AA06, trimipramine, Trimipramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R06AX07, triprolidine, Triprolidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[A03BB01, butylscopolamine, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[N06AX24, vilazodone, Vilazodone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N06AX02, tryptophan, Tryptophan may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C09CA09, azilsartan medoxomil, The risk or severity of adverse effects can be increased when Thalidomide is combined with Azilsartan medoxomil.]
[M03AA02, tubocurarine, Tubocurarine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DX07, roflumilast, Roflumilast may increase the immunosuppressive activities of Thalidomide.]
[L04AA26, belimumab, The risk or severity of adverse effects can be increased when Thalidomide is combined with Belimumab.]
[J05AP03, boceprevir, The metabolism of Boceprevir can be increased when combined with Thalidomide.]
[J05AP02, telaprevir, The metabolism of Telaprevir can be increased when combined with Thalidomide.]
[J05AG05, rilpivirine, The serum concentration of Rilpivirine can be decreased when it is combined with Thalidomide.]
[B01AD04, urokinase, The risk or severity of bleeding can be increased when Urokinase is combined with Thalidomide.]
[L04AA28, belatacept, The risk or severity of adverse effects can be increased when Thalidomide is combined with Belatacept.]
[N03AX21, ezogabine, Ezogabine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[B01AF01, rivaroxaban, The metabolism of Rivaroxaban can be increased when combined with Thalidomide.]
[B01AC24, ticagrelor, The metabolism of Ticagrelor can be increased when combined with Thalidomide.]
[C08DA01, verapamil, The metabolism of Verapamil can be increased when combined with Thalidomide.]
[N06AX09, viloxazine, Viloxazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L01CA01, vinblastine, The risk or severity of adverse effects can be increased when Vinblastine is combined with Thalidomide.]
[C04AX07, vincamine, Thalidomide may increase the hypotensive activities of Vincamine.]
[L01CA02, vincristine, The risk or severity of peripheral neuropathy can be increased when Thalidomide is combined with Vincristine.]
[L01CA03, vindesine, The risk or severity of adverse effects can be increased when Vindesine is combined with Thalidomide.]
[B03BA01, vitamin B12, The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Thalidomide.]
[B01AA03, warfarin, The risk or severity of bleeding can be increased when Thalidomide is combined with Warfarin.]
[C03BA10, xipamide, Thalidomide may increase the hypotensive activities of Xipamide.]
[J05AF01, zidovudine, The risk or severity of adverse effects can be increased when Zidovudine is combined with Thalidomide.]
[N05AF05, zuclopenthixol, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[J05AE02, indinavir, The metabolism of Indinavir can be increased when combined with Thalidomide.]
[N03AX14, levetiracetam, Levetiracetam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L01EC01, vemurafenib, The metabolism of Thalidomide can be decreased when combined with Vemurafenib.]
[M05BA03, pamidronic acid, The risk or severity of nephrotoxicity can be increased when Thalidomide is combined with Pamidronic acid.]
[L01FX05, brentuximab vedotin, The risk or severity of adverse effects can be increased when Thalidomide is combined with Brentuximab vedotin.]
[M05BA05, tiludronic acid, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Thalidomide is combined with Tiludronic acid.]
[L01ED01, crizotinib, The metabolism of Crizotinib can be increased when combined with Thalidomide.]
[B01AE01, desirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Thalidomide.]
[R03DC01, zafirlukast, The metabolism of Thalidomide can be decreased when combined with Zafirlukast.]
[M05BA06, ibandronic acid, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Thalidomide is combined with Ibandronate.]
[N05AE04, ziprasidone, Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[G03AC10, drospirenone, Drospirenone may increase the thrombogenic activities of Thalidomide.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Thalidomide.]
[N02BA01, aspirin, The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Thalidomide.]
[L01EJ01, ruxolitinib, The risk or severity of adverse effects can be increased when Thalidomide is combined with Ruxolitinib.]
[G04BD07, tolterodine, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[C07AB03, atenolol, The risk or severity of adverse effects can be increased when Atenolol is combined with Thalidomide.]
[L03AB11, peginterferon alfa-2a, The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Thalidomide.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Rituximab is combined with Thalidomide.]
[J02AC03, voriconazole, The metabolism of Thalidomide can be decreased when combined with Voriconazole.]
[M03AC04, atracurium, Atracurium may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[S01FA01, atropine, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[L01XJ01, vismodegib, The metabolism of Vismodegib can be decreased when combined with Thalidomide.]
[L01EK01, axitinib, The metabolism of Axitinib can be increased when combined with Thalidomide.]
[R07AX02, ivacaftor, The metabolism of Ivacaftor can be increased when combined with Thalidomide.]
[H02AB11, prednylidene, The risk or severity of adverse effects can be increased when Thalidomide is combined with Prednylidene.]
[B03XA04, peginesatide, The risk or severity of thromboembolism can be increased when Thalidomide is combined with Peginesatide.]
[L01BC07, azacitidine, The risk or severity of adverse effects can be increased when Azacitidine is combined with Thalidomide.]
[L04AX01, azathioprine, The risk or severity of adverse effects can be increased when Azathioprine is combined with Thalidomide.]
[L01BC05, gemcitabine, The risk or severity of adverse effects can be increased when Gemcitabine is combined with Thalidomide.]
[G04BE10, avanafil, The metabolism of Avanafil can be decreased when combined with Thalidomide.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Thalidomide.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Thalidomide.]
[L01FD02, pertuzumab, The risk or severity of cardiotoxicity can be increased when Thalidomide is combined with Pertuzumab.]
[A08AA11, lorcaserin, Lorcaserin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L01XG02, carfilzomib, The risk or severity of adverse effects can be increased when Thalidomide is combined with Carfilzomib.]
[V03AX03, cobicistat, The metabolism of Cobicistat can be increased when combined with Thalidomide.]
[L02BB04, enzalutamide, The serum concentration of Thalidomide can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The risk or severity of adverse effects can be increased when Thalidomide is combined with Bosutinib.]
[L04AA31, teriflunomide, The risk or severity of adverse effects can be increased when Thalidomide is combined with Teriflunomide.]
[B01AX01, defibrotide, The risk or severity of bleeding can be increased when Defibrotide is combined with Thalidomide.]
[L04AA22, abetimus, The risk or severity of adverse effects can be increased when Thalidomide is combined with Abetimus.]
[H02AA01, aldosterone, The risk or severity of adverse effects can be increased when Thalidomide is combined with Aldosterone.]
[L01EX05, regorafenib, The metabolism of Thalidomide can be decreased when combined with Regorafenib.]
[N05CA04, barbital, Barbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C01AA01, acetyldigitoxin, Acetyldigitoxin may decrease the cardiotoxic activities of Thalidomide.]
[L01AA09, bendamustine, The risk or severity of adverse effects can be increased when Thalidomide is combined with Bendamustine.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N04BD02, rasagiline, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C08CA13, lercanidipine, The metabolism of Lercanidipine can be increased when combined with Thalidomide.]
[A03FA09, mosapride, Mosapride may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N06DA02, donepezil, Donepezil may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L04AA29, tofacitinib, Thalidomide may increase the immunosuppressive activities of Tofacitinib.]
[N02CC03, zolmitriptan, Zolmitriptan may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R06AC06, thonzylamine, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.]
[N01AA01, ethyl ether, Diethyl ether may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L01EX07, cabozantinib, The metabolism of Cabozantinib can be decreased when combined with Thalidomide.]
[G04BE03, sildenafil, The metabolism of Sildenafil can be increased when combined with Thalidomide.]
[L01EA05, ponatinib, The risk or severity of adverse effects can be increased when Thalidomide is combined with Ponatinib.]
[B01AF02, apixaban, The metabolism of Apixaban can be increased when combined with Thalidomide.]
[C03AA01, bendroflumethiazide, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Thalidomide.]
[L04AX06, pomalidomide, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[G03XC05, ospemifene, The metabolism of Ospemifene can be decreased when combined with Thalidomide.]
[N05AD07, benperidol, Benperidol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[A10BK02, canagliflozin, The risk or severity of adverse effects can be increased when Thalidomide is combined with Canagliflozin.]
[L04AX07, dimethyl fumarate, The risk or severity of adverse effects can be increased when Thalidomide is combined with Dimethyl fumarate.]
[M04AB03, benzbromarone, The metabolism of Thalidomide can be decreased when combined with Benzbromarone.]
[R02AD01, benzocaine, Benzocaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[M01AH01, celecoxib, The metabolism of Thalidomide can be decreased when combined with Celecoxib.]
[N02CC02, naratriptan, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L04AA18, everolimus, The risk or severity of adverse effects can be increased when Thalidomide is combined with Everolimus.]
[N04AC01, benztropine, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.]
[L01EC02, dabrafenib, The serum concentration of Thalidomide can be decreased when it is combined with Dabrafenib.]
[P03AX06, benzyl alcohol, Benzyl alcohol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N06AX28, levomilnacipran, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C08EA02, bepridil, The risk or severity of adverse effects can be increased when Thalidomide is combined with Bepridil.]
[C02KX05, riociguat, The risk or severity of adverse effects can be increased when Thalidomide is combined with Riociguat.]
[L03AA14, lipegfilgrastim, Thalidomide may increase the myelosuppressive activities of Lipegfilgrastim.]
[C02KX04, macitentan, Thalidomide may increase the hypotensive activities of Macitentan.]
[L01EL01, ibrutinib, The risk or severity of adverse effects can be increased when Thalidomide is combined with Ibrutinib.]
[N06AX26, vortioxetine, Vortioxetine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[G03AC08, etonogestrel, Etonogestrel may increase the thrombogenic activities of Thalidomide.]
[N03AF04, eslicarbazepine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N03AG04, vigabatrin, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[A10BK01, dapagliflozin, The risk or severity of adverse effects can be increased when Thalidomide is combined with Dapagliflozin.]
[C07AB04, acebutolol, The risk or severity of adverse effects can be increased when Thalidomide is combined with Acebutolol.]
[N05CH03, tasimelteon, Tasimelteon may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L04AA32, apremilast, The metabolism of Thalidomide can be increased when combined with Apremilast.]
[S03BA03, betamethasone, The risk or severity of adverse effects can be increased when Betamethasone is combined with Thalidomide.]
[S01ED02, betaxolol, The risk or severity of adverse effects can be increased when Betaxolol is combined with Thalidomide.]
[B01AE03, argatroban, The risk or severity of bleeding can be increased when Argatroban is combined with Thalidomide.]
[C02CC01, bethanidine, Thalidomide may increase the hypotensive activities of Bethanidine.]
[L04AC11, siltuximab, The metabolism of Thalidomide can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The metabolism of Thalidomide can be decreased when combined with Ceritinib.]
[B01AC26, vorapaxar, The risk or severity of bleeding can be increased when Vorapaxar is combined with Thalidomide.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Thalidomide is combined with Vedolizumab.]
[A03BA03, hyoscyamine, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.]
[B01AA07, acenocoumarol, The risk or severity of bleeding can be increased when Thalidomide is combined with Acenocoumarol.]
[L01XH04, belinostat, The risk or severity of adverse effects can be increased when Thalidomide is combined with Belinostat.]
[L01EM01, idelalisib, The risk or severity of adverse effects can be increased when Thalidomide is combined with Idelalisib.]
[N01AX05, alfaxalone, Alfaxalone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[A10BK03, empagliflozin, The risk or severity of adverse effects can be increased when Thalidomide is combined with Empagliflozin.]
[R03AC19, olodaterol, The metabolism of Olodaterol can be decreased when combined with Thalidomide.]
[L03AB13, peginterferon beta-1a, The risk or severity of adverse effects can be increased when Thalidomide is combined with Peginterferon beta-1a.]
[D11AA01, glycopyrronium, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[N05CM19, suvorexant, Suvorexant may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[J01XA05, oritavancin, The metabolism of Thalidomide can be decreased when combined with Oritavancin.]
[N05AA04, acepromazine, Acepromazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L01BC08, decitabine, The risk or severity of adverse effects can be increased when Thalidomide is combined with Decitabine.]
[N04AA02, biperiden, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[L04AX05, pirfenidone, The risk or severity of adverse effects can be increased when Thalidomide is combined with Pirfenidone.]
[L01FX07, blinatumomab, The risk or severity of adverse effects can be increased when Thalidomide is combined with Blinatumomab.]
[L01XK01, olaparib, The risk or severity of adverse effects can be increased when Thalidomide is combined with Olaparib.]
[B01AA01, dicumarol, The risk or severity of bleeding can be increased when Thalidomide is combined with Dicoumarol.]
[B01AF03, edoxaban, The risk or severity of bleeding can be increased when Edoxaban is combined with Thalidomide.]
[N06AX11, mirtazapine, Mirtazapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L04AC10, secukinumab, The metabolism of Thalidomide can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The risk or severity of adverse effects can be increased when Thalidomide is combined with Palbociclib.]
[L01XH03, panobinostat, The risk or severity of adverse effects can be increased when Thalidomide is combined with Panobinostat.]
[J05AP07, daclatasvir, The metabolism of Daclatasvir can be increased when combined with Thalidomide.]
[L01DC01, bleomycin, The risk or severity of adverse effects can be increased when Bleomycin is combined with Thalidomide.]
[A03AA09, difemerine, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[B01AA11, tioclomarol, The risk or severity of bleeding can be increased when Thalidomide is combined with Tioclomarol.]
[J05AP06, asunaprevir, The metabolism of Asunaprevir can be increased when combined with Thalidomide.]
[B01AC25, cangrelor, The risk or severity of bleeding can be increased when Cangrelor is combined with Thalidomide.]
[N05AX16, brexpiprazole, Brexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[G02CX02, flibanserin, Flibanserin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05AX15, cariprazine, Cariprazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[S01EC01, acetazolamide, Acetazolamide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05AB07, acetophenazine, Acetophenazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[A02BC03, lansoprazole, The metabolism of Thalidomide can be decreased when combined with Lansoprazole.]
[L01CX01, trabectedin, The risk or severity of adverse effects can be increased when Thalidomide is combined with Trabectedin.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Thalidomide is combined with Mepolizumab.]
[J02AC05, isavuconazole, The metabolism of Isavuconazole can be increased when combined with Thalidomide.]
[B01AC27, selexipag, Thalidomide may increase the hypotensive activities of Selexipag.]
[A10BB31, acetohexamide, The metabolism of Thalidomide can be decreased when combined with Acetohexamide.]
[M04AB05, lesinurad, The metabolism of Lesinurad can be decreased when combined with Thalidomide.]
[J05AP10, elbasvir, The metabolism of Elbasvir can be increased when combined with Thalidomide.]
[N05CA05, aprobarbital, Aprobarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N03AX23, brivaracetam, Brivaracetam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Thalidomide is combined with Ixekizumab.]
[N05BA08, bromazepam, Bromazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N04BC01, bromocriptine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[A03AX08, alverine, Alverine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R06AB01, brompheniramine, Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N06AA19, amineptin, Amineptine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C08CA01, amlodipine, The risk or severity of adverse effects can be increased when Amlodipine is combined with Thalidomide.]
[N06BX11, aniracetam, Aniracetam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C03CA02, bumetanide, The risk or severity of adverse effects can be increased when Bumetanide is combined with Thalidomide.]
[N01BB01, bupivacaine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C07AA19, bupranolol, Thalidomide may increase the hypotensive activities of Bupranolol.]
[N07BC01, buprenorphine, Buprenorphine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05BE01, buspirone, Buspirone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L01AB01, busulfan, The risk or severity of adverse effects can be increased when Busulfan is combined with Thalidomide.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Thalidomide is combined with Arsenic trioxide.]
[P01BE02, artemether, The metabolism of Artemether can be increased when combined with Thalidomide.]
[N02AF01, butorphanol, Butorphanol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[S01GX07, azelastine, Azelastine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L01XK03, rucaparib, The metabolism of Thalidomide can be decreased when combined with Rucaparib.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Thalidomide is combined with Brodalumab.]
[L04AA36, ocrelizumab, The risk or severity of adverse effects can be increased when Thalidomide is combined with Ocrelizumab.]
[N07XX16, deutetrabenazine, The metabolism of Deutetrabenazine can be increased when combined with Thalidomide.]
[N02BF02, pregabalin, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N03AX30, beclamide, Beclamide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C09AA07, benazepril, The risk or severity of adverse effects can be increased when Benazepril is combined with Thalidomide.]
[S01HA02, benoxinate, Oxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L04AC01, daclizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Thalidomide.]
[J01XX08, linezolid, The risk or severity of adverse effects can be increased when Linezolid is combined with Thalidomide.]
[N07XX13, valbenazine, The metabolism of Valbenazine can be increased when combined with Thalidomide.]
[L04AB02, infliximab, The metabolism of Thalidomide can be increased when combined with Infliximab.]
[N04BD03, safinamide, Safinamide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L04AC14, sarilumab, The risk or severity of adverse effects can be increased when Thalidomide is combined with Sarilumab.]
[J01MA23, delafloxacin, The metabolism of Thalidomide can be increased when combined with Delafloxacin.]
[B01AF04, betrixaban, The risk or severity of bleeding can be increased when Betrixaban is combined with Thalidomide.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Thalidomide is combined with Guselkumab.]
[L01BC06, capecitabine, The risk or severity of adverse effects can be increased when Thalidomide is combined with Capecitabine.]
[L01XX59, enasidenib, The metabolism of Thalidomide can be decreased when combined with Enasidenib.]
[L01XH01, vorinostat, The risk or severity of adverse effects can be increased when Thalidomide is combined with Vorinostat.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be increased when combined with Thalidomide.]
[C07AB07, bisoprolol, The risk or severity of adverse effects can be increased when Bisoprolol is combined with Thalidomide.]
[J05AG03, efavirenz, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N04AA11, bornaprine, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Basiliximab is combined with Thalidomide.]
[L01BA03, raltitrexed, The risk or severity of adverse effects can be increased when Raltitrexed is combined with Thalidomide.]
[V03AF08, palifermin, The therapeutic efficacy of Palifermin can be decreased when used in combination with Thalidomide.]
[C01DX19, nesiritide, The risk or severity of adverse effects can be increased when Thalidomide is combined with Nesiritide.]
[N05AD06, bromperidol, Bromperidol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05CD09, brotizolam, Brotizolam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03BA02, budesonide, The risk or severity of adverse effects can be increased when Thalidomide is combined with Budesonide.]
[C04AX20, buflomedil, The risk or severity of bleeding can be increased when Buflomedil is combined with Thalidomide.]
[N05CA03, butobarbital, Butobarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N06AA15, butriptyline, Butriptyline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C01AA02, acetyldigoxins, Acetyldigoxin may decrease the cardiotoxic activities of Thalidomide.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Thalidomide is combined with Capsaicin.]
[N05CA08, butylvinal, Vinylbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C09AA01, captopril, The risk or severity of adverse effects can be increased when Thalidomide is combined with Captopril.]
[L02BB05, apalutamide, The metabolism of Thalidomide can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, Carbamazepine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[A03AA03, camylofine, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[R06AA08, carbinoxamine, Carbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L03AB06, interferon alfa-n1, The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Thalidomide.]
[C07AG02, carvedilol, The risk or severity of adverse effects can be increased when Thalidomide is combined with Carvedilol.]
[B02BX09, fostamatinib, The risk or severity of hypotension can be increased when Fostamatinib is combined with Thalidomide.]
[N03AX24, cannabidiol, Cannabidiol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[B02BX08, avatrombopag, The metabolism of Thalidomide can be increased when combined with Avatrombopag.]
[L04AA37, baricitinib, The risk or severity of adverse effects can be increased when Thalidomide is combined with Baricitinib.]
[C07AB08, celiprolol, Thalidomide may increase the hypotensive activities of Celiprolol.]
[L01XX62, ivosidenib, The metabolism of Thalidomide can be increased when combined with Ivosidenib.]
[N03AX17, stiripentol, Stiripentol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[J05AG06, doravirine, The metabolism of Doravirine can be increased when combined with Thalidomide.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Thalidomide.]
[S01GX12, cetirizine, Cetirizine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05CM04, carbromal, Carbromal may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[A10BB06, carbutamide, The metabolism of Carbutamide can be decreased when combined with Thalidomide.]
[N01BA04, chloroprocaine, Chloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R06AA06, chlorphenoxamine, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[M01AC05, lornoxicam, The metabolism of Lornoxicam can be decreased when combined with Thalidomide.]
[M03BA02, carisoprodol, Carisoprodol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03BB08, revefenacin, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[L01ED05, lorlatinib, The metabolism of Lorlatinib can be increased when combined with Thalidomide.]
[L04AA39, emapalumab, The metabolism of Thalidomide can be increased when combined with Emapalumab.]
[L01AD01, carmustine, The risk or severity of adverse effects can be increased when Carmustine is combined with Thalidomide.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Thalidomide is combined with Ravulizumab.]
[C09AA08, cilazapril, The risk or severity of adverse effects can be increased when Thalidomide is combined with Cilazapril.]
[B01AX07, caplacizumab, The risk or severity of bleeding can be increased when Caplacizumab is combined with Thalidomide.]
[B01AC23, cilostazol, The serum concentration of Cilostazol can be increased when it is combined with Thalidomide.]
[A03FA08, cinitapride, Cinitapride may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[P02BX04, triclabendazole, The metabolism of Thalidomide can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, Esketamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L04AA42, siponimod, The risk or severity of adverse effects can be increased when Thalidomide is combined with Siponimod.]
[J01FA09, clarithromycin, The metabolism of Clarithromycin can be increased when combined with Thalidomide.]
[N06BA14, solriamfetol, Solriamfetol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N06AX29, brexanolone, Brexanolone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be decreased when combined with Thalidomide.]
[N05BA09, clobazam, Clobazam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[H02AB14, cloprednol, The risk or severity of adverse effects can be increased when Thalidomide is combined with Cloprednol.]
[N05BA22, cloxazolam, Cloxazolam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C09CA06, candesartan, The metabolism of Thalidomide can be decreased when combined with Candesartan.]
[L04AB01, etanercept, The metabolism of Thalidomide can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The risk or severity of adverse effects can be increased when Thalidomide is combined with Cortivazol.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Thalidomide is combined with Risankizumab.]
[L01EM03, alpelisib, The serum concentration of Thalidomide can be decreased when it is combined with Alpelisib.]
[N05AA06, cyamemazine, Cyamemazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C03BX03, cicletanine, Thalidomide may increase the hypotensive activities of Cicletanine.]
[M03BX08, cyclobenzaprine, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L04AA44, upadacitinib, The risk or severity of adverse effects can be increased when Thalidomide is combined with Upadacitinib.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be increased when combined with Thalidomide.]
[C03AA09, cyclothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Thalidomide.]
[G04BE04, yohimbine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[H02AB13, deflazacort, The risk or severity of adverse effects can be increased when Thalidomide is combined with Deflazacort.]
[G03DB05, demegestone, Demegestone may increase the thrombogenic activities of Thalidomide.]
[L01FD01, trastuzumab, Trastuzumab may increase the neutropenic activities of Thalidomide.]
[L01FD03, ado-trastuzumab emtansine, The risk or severity of adverse effects can be increased when Thalidomide is combined with Trastuzumab emtansine.]
[N02CC08, lasmiditan, Lasmiditan may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L04AX09, diroximel fumarate, The risk or severity of adverse effects can be increased when Thalidomide is combined with Diroximel fumarate.]
[G03AC09, desogestrel, Desogestrel may increase the thrombogenic activities of Thalidomide.]
[B06AX03, voxelotor, The metabolism of Voxelotor can be decreased when combined with Thalidomide.]
[N03AX25, cenobamate, The metabolism of Cenobamate can be increased when combined with Thalidomide.]
[R06AB06, dexbrompheniramine, Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N02AX03, dezocine, Dezocine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L01EX18, avapritinib, The metabolism of Thalidomide can be decreased when combined with Avapritinib.]
[N05CM21, lemborexant, Lemborexant may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L04AA53, teprotumumab, The risk or severity of adverse effects can be increased when Thalidomide is combined with Teprotumumab.]
[N05AD10, lumateperone, Lumateperone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[M01AX21, diacetylrhein, The metabolism of Thalidomide can be decreased when combined with Diacerein.]
[N02CD06, rimegepant, The metabolism of Rimegepant can be increased when combined with Thalidomide.]
[J05AE05, amprenavir, The metabolism of Amprenavir can be increased when combined with Thalidomide.]
[N02CC07, frovatriptan, Frovatriptan may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[G04CB02, dutasteride, The metabolism of Dutasteride can be increased when combined with Thalidomide.]
[L04AA38, ozanimod, The risk or severity of adverse effects can be increased when Thalidomide is combined with Ozanimod.]
[N05CC04, dichloralphenazone, Dichloralphenazone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be increased when combined with Thalidomide.]
[G03DB08, dienogest, Dienogest may increase the thrombogenic activities of Thalidomide.]
[A07DA04, difenoxin, Difenoxin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N02AA08, dihydrocodeine, Dihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N02CC06, eletriptan, Eletriptan may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[M01AH02, rofecoxib, The metabolism of Thalidomide can be decreased when combined with Rofecoxib.]
[L01XF03, bexarotene, The risk or severity of adverse effects can be increased when Bexarotene is combined with Thalidomide.]
[C08CA16, clevidipine, The metabolism of Thalidomide can be decreased when combined with Clevidipine.]
[C01BD07, dronedarone, The metabolism of Dronedarone can be increased when combined with Thalidomide.]
[N03AG02, dipropylacetamide, Valpromide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L01AA02, chlorambucil, The risk or severity of adverse effects can be increased when Chlorambucil is combined with Thalidomide.]
[S03AA08, chloramphenicol, The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Thalidomide.]
[N05BA02, chlordiazepoxide, Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C02AA06, methoserpidine, Thalidomide may increase the hypotensive activities of Methoserpidine.]
[A03AA08, dihexyverine, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[L01EX17, capmatinib, The serum concentration of Capmatinib can be decreased when it is combined with Thalidomide.]
[N04BX04, opicapone, The risk or severity of adverse effects can be increased when Thalidomide is combined with Opicapone.]
[D07XB03, fluprednidene, The risk or severity of adverse effects can be increased when Thalidomide is combined with Fluprednidene.]
[G04BD09, trospium, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[L01EX22, selpercatinib, The serum concentration of Selpercatinib can be decreased when it is combined with Thalidomide.]
[B01AE02, lepirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Thalidomide.]
[N05CM02, chlormethiazole, Clomethiazole may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[M03BB02, chlormezanone, Chlormezanone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L04AA47, inebilizumab, The risk or severity of infection can be increased when Thalidomide is combined with Inebilizumab.]
[R02AD04, dyclonine, Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R05CB11, stepronin, The risk or severity of adverse effects can be increased when Thalidomide is combined with Stepronin.]
[C08CA17, levamlodipine, The metabolism of Levamlodipine can be increased when combined with Thalidomide.]
[P01BB01, proguanil, The metabolism of Proguanil can be decreased when combined with Thalidomide.]
[N05CD14, remimazolam, Remimazolam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N07XX04, sodium oxybate, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[L04AC19, satralizumab, The serum concentration of Thalidomide can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, Oliceridine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[P01BA01, chloroquine, The metabolism of Chloroquine can be increased when combined with Thalidomide.]
[L01EX23, pralsetinib, The metabolism of Thalidomide can be decreased when combined with Pralsetinib.]
[C03AA04, chlorothiazide, The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Thalidomide.]
[G03CA06, chlorotrianisene, Chlorotrianisene may increase the thrombogenic activities of Thalidomide.]
[R06AB04, chlorpheniramine, Chlorpheniramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05AA01, chlorpromazine, Chlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[A10BB02, chlorpropamide, The metabolism of Thalidomide can be decreased when combined with Chlorpropamide.]
[N05AF03, chlorprothixene, Chlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C03BA04, chlorthalidone, The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Thalidomide.]
[M03BB03, chlorzoxazone, Chlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05BX03, etifoxine, Etifoxine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N06BX18, vinpocetine, Vinpocetine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05BA18, ethyl loflazepate, Ethyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[G03DC06, ethynodiol, Etynodiol may increase the thrombogenic activities of Thalidomide.]
[M01AB08, etodolac, The metabolism of Thalidomide can be decreased when combined with Etodolac.]
[A16AX20, lonafarnib, The metabolism of Lonafarnib can be increased when combined with Thalidomide.]
[L01BB05, fludarabine, The risk or severity of adverse effects can be increased when Thalidomide is combined with Fludarabine.]
[L02BX04, relugolix, The metabolism of Relugolix can be increased when combined with Thalidomide.]
[L04AD03, voclosporin, The risk or severity of adverse effects can be increased when Thalidomide is combined with Voclosporin.]
[C01DX22, vericiguat, The risk or severity of adverse effects can be increased when Thalidomide is combined with Vericiguat.]
[L01EX21, tepotinib, The metabolism of Thalidomide can be decreased when combined with Tepotinib.]
[M03BA05, febarbamate, Febarbamate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N03AX10, felbamate, Felbamate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C01CA19, fenoldopam, The risk or severity of adverse effects can be increased when Fenoldopam is combined with Thalidomide.]
[G04CB01, finasteride, The metabolism of Finasteride can be increased when combined with Thalidomide.]
[R03BA03, flunisolide, The risk or severity of adverse effects can be increased when Flunisolide is combined with Thalidomide.]
[S02BA08, fluocinolone acetonide, The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Thalidomide.]
[R03CC15, formoterol, The metabolism of Thalidomide can be decreased when combined with Formoterol.]
[L04AA50, ponesimod, The risk or severity of adverse effects can be increased when Thalidomide is combined with Ponesimod.]
[S01LA08, bevacizumab, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Thalidomide.]
[N01AB05, trichloroethylene, Trichloroethylene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L03AB10, peginterferon alfa-2b, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Thalidomide.]
[H04AA02, dasiglucagon, Thalidomide may increase the hypotensive activities of Dasiglucagon.]
[A02BA01, cimetidine, The metabolism of Thalidomide can be decreased when combined with Cimetidine.]
[N02BF01, gabapentin, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N07CA02, cinnarizine, The metabolism of Thalidomide can be decreased when combined with Cinnarizine.]
[L01XA01, cisplatin, The risk or severity of peripheral neuropathy can be increased when Thalidomide is combined with Cisplatin.]
[N06AB04, citalopram, Citalopram may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L04AA54, pegcetacoplan, The risk or severity of adverse effects can be increased when Thalidomide is combined with Pegcetacoplan.]
[L04AA48, belumosudil, The risk or severity of adverse effects can be increased when Thalidomide is combined with Belumosudil.]
[P01CA03, fexinidazole, The metabolism of Fexinidazole can be increased when combined with Thalidomide.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Thalidomide is combined with Anifrolumab.]
[L01XX74, belzutifan, The serum concentration of Belzutifan can be increased when it is combined with Thalidomide.]
[L01EB10, mobocertinib, The metabolism of Mobocertinib can be increased when combined with Thalidomide.]
[R06AA04, clemastine, Clemastine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[M01AG01, mefenamic acid, The metabolism of Thalidomide can be decreased when combined with Mefenamic acid.]
[A10BB12, glimepiride, The metabolism of Thalidomide can be decreased when combined with Glimepiride.]
[A10BB08, gliquidone, The metabolism of Gliquidone can be decreased when combined with Thalidomide.]
[J01FF01, clindamycin, The metabolism of Clindamycin can be increased when combined with Thalidomide.]
[N06AX25, St. John's wort extract, St. John's Wort may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L01EA06, asciminib, The metabolism of Thalidomide can be decreased when combined with Asciminib.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Thalidomide.]
[D11AH08, abrocitinib, The metabolism of Abrocitinib can be decreased when combined with Thalidomide.]
[B01AD11, tenecteplase, The risk or severity of bleeding can be increased when Tenecteplase is combined with Thalidomide.]
[N01BB10, levobupivacaine, Levobupivacaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N06AA04, clomipramine, Clomipramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N03AE01, clonazepam, Clonazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[S01EA04, clonidine, Clonidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C01EB24, mavacamten, The serum concentration of Thalidomide can be decreased when it is combined with Mavacamten.]
[A02BC08, vonoprazan, The metabolism of Vonoprazan can be increased when combined with Thalidomide.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Thalidomide is combined with Spesolimab.]
[L04AA56, deucravacitinib, The risk or severity of adverse effects can be increased when Thalidomide is combined with Deucravacitinib.]
[N05AH06, clothiapine, Clothiapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05BA21, clotiazepam, Clotiazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[A04AA01, ondansetron, Ondansetron may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[A04AA02, granisetron, Granisetron may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05AH02, clozapine, Clozapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05BA13, halazepam, Halazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Thalidomide is combined with Cocaine.]
[C02KB01, metyrosine, Thalidomide may increase the sedative activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Thalidomide can be increased when combined with Bimekizumab.]
[R05DA04, codeine, Codeine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[M03AC05, hexafluorenium, Hexafluronium may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[A03AB10, hexocyclium, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[L04AA13, leflunomide, The risk or severity of adverse effects can be increased when Thalidomide is combined with Leflunomide.]
[N01AB07, desflurane, Desflurane may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[A04AA03, tropisetron, Tropisetron may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C04AX28, ifenprodil, Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[A10BX03, nateglinide, The metabolism of Nateglinide can be increased when combined with Thalidomide.]
[L01BB07, nelarabine, The risk or severity of adverse effects can be increased when Thalidomide is combined with Nelarabine.]
[J01FA15, telithromycin, The metabolism of Telithromycin can be increased when combined with Thalidomide.]
[R03BA08, ciclesonide, The risk or severity of adverse effects can be increased when Thalidomide is combined with Ciclesonide.]
[B01AC10, indobufen, The risk or severity of bleeding can be increased when Indobufen is combined with Thalidomide.]
[R06AX27, desloratadine, Desloratadine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[M01AH03, valdecoxib, The metabolism of Thalidomide can be decreased when combined with Valdecoxib.]
[C01AA06, lanatoside C, Lanatoside C may decrease the cardiotoxic activities of Thalidomide.]
[N02CC05, almotriptan, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[M01AH04, parecoxib, The metabolism of Parecoxib can be decreased when combined with Thalidomide.]
[B01AB12, bemiparin, The risk or severity of bleeding can be increased when Bemiparin is combined with Thalidomide.]
[N05BA10, ketazolam, Ketazolam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L01EA01, imatinib, The risk or severity of adverse effects can be increased when Imatinib is combined with Thalidomide.]
[C08CA09, lacidipine, Thalidomide may increase the hypotensive activities of Lacidipine.]
[B03XA02, darbepoetin alfa, The risk or severity of thromboembolism can be increased when Thalidomide is combined with Darbepoetin alfa.]
[N03AX09, lamotrigine, Lamotrigine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[S01GX02, levocabastine, Levocabastine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N07BC04, lofexidine, Lofexidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05CD06, lormetazepam, Lormetazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C09AA03, lisinopril, The risk or severity of adverse effects can be increased when Lisinopril is combined with Thalidomide.]
[C08CA11, manidipine, The metabolism of Thalidomide can be decreased when combined with Manidipine.]
[A03AA04, mebeverine, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, Medifoxamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[H02AB15, meprednisone, The risk or severity of adverse effects can be increased when Thalidomide is combined with Meprednisone.]
[N04AA03, methixene, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[R06AE03, cyclizine, Cyclizine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05CA10, cyclobarbital, Cyclobarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C03DA04, eplerenone, The metabolism of Eplerenone can be increased when combined with Thalidomide.]
[N05AD03, metylperon, Melperone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L04AA15, alefacept, The risk or severity of adverse effects can be increased when Alefacept is combined with Thalidomide.]
[C03AA07, cyclopenthiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Thalidomide.]
[L01AA01, cyclophosphamide, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Thalidomide.]
[N06AX07, minaprine, Minaprine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[S01XA18, cyclosporine, Thalidomide may increase the immunosuppressive activities of Cyclosporine.]
[N06AG02, moclobemide, Moclobemide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N06BA07, modafinil, The metabolism of Modafinil can be increased when combined with Thalidomide.]
[R06AX02, cyproheptadine, Cyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C09AA13, moexipril, The risk or severity of adverse effects can be increased when Moexipril is combined with Thalidomide.]
[C10AA07, rosuvastatin, The metabolism of Rosuvastatin can be increased when combined with Thalidomide.]
[C03XA02, conivaptan, The risk or severity of adverse effects can be increased when Conivaptan is combined with Thalidomide.]
[C02AC05, moxonidine, The risk or severity of adverse effects can be increased when Thalidomide is combined with Moxonidine.]
[L01BC01, cytarabine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Thalidomide.]
[G04BE09, vardenafil, The metabolism of Vardenafil can be increased when combined with Thalidomide.]
[M01AH05, etoricoxib, The metabolism of Thalidomide can be decreased when combined with Etoricoxib.]
[L01AX04, dacarbazine, The risk or severity of adverse effects can be increased when Dacarbazine is combined with Thalidomide.]
[L01DA01, dactinomycin, The risk or severity of adverse effects can be increased when Dactinomycin is combined with Thalidomide.]
[M03CA01, dantrolene, Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[J04BA02, dapsone, The metabolism of Dapsone can be increased when combined with Thalidomide.]
[L01DB02, daunorubicin, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Thalidomide.]
[N06BX04, deanol, Deanol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C02CC04, debrisoquin, Thalidomide may increase the hypotensive activities of Debrisoquine.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[M01AX01, nabumetone, The metabolism of Thalidomide can be decreased when combined with Nabumetone.]
[N05BA16, nordazepam, Nordazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C07AB12, nebivolol, The risk or severity of adverse effects can be increased when Thalidomide is combined with Nebivolol.]
[N06AX06, nefazodone, Nefazodone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05CM16, niaprazine, Niaprazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C01DX16, nicorandil, Nicorandil may increase the hypotensive activities of Thalidomide.]
[L02BB02, nilutamide, The metabolism of Thalidomide can be decreased when combined with Nilutamide.]
[N03AG06, tiagabine, Tiagabine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[G03DB04, nomegestrol, Nomegestrol may increase the thrombogenic activities of Thalidomide.]
[M03AC11, cisatracurium, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R05DA06, normethadone, Normethadone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[B01AX05, fondaparinux, The risk or severity of bleeding can be increased when Fondaparinux is combined with Thalidomide.]
[D11AH02, pimecrolimus, The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Thalidomide.]
[N06AB10, escitalopram, Escitalopram may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[G04BD08, solifenacin, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[N06AA01, desipramine, Desipramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C01AA07, deslanoside, Deslanoside may decrease the cardiotoxic activities of Thalidomide.]
[D07XC02, desoximetasone, The risk or severity of adverse effects can be increased when Desoximetasone is combined with Thalidomide.]
[C09XA02, aliskiren, The risk or severity of adverse effects can be increased when Thalidomide is combined with Aliskiren.]
[L01XA03, oxaliplatin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Thalidomide.]
[N03AF02, oxcarbazepine, Oxcarbazepine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[S03BA01, dexamethasone, The risk or severity of thromboembolism can be increased when Dexamethasone is combined with Thalidomide.]
[N06BX07, oxiracetam, Oxiracetam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N04AA08, dexetimide, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A03AA01, oxyphencyclimine, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[L04AB04, adalimumab, The metabolism of Thalidomide can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Gefitinib can be increased when combined with Thalidomide.]
[R05DA09, dextromethorphan, Dextromethorphan may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N03AC01, paramethadione, Paramethadione may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N02AC01, dextromoramide, Dextromoramide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N06AB05, paroxetine, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[B01AC04, clopidogrel, The metabolism of Clopidogrel can be increased when combined with Thalidomide.]
[N07BC06, heroin, Diamorphine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05BA01, diazepam, Diazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N03AX07, phenacemide, Phenacemide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[V03AH01, diazoxide, The risk or severity of adverse effects can be increased when Thalidomide is combined with Diazoxide.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Thalidomide is combined with Phenol.]
[N03AD02, phensuximide, Phensuximide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N06AA08, dibenzepin, Dibenzepin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[S02DA04, dibucaine, Cinchocaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[M05BA02, clodronic acid, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Thalidomide is combined with Clodronic acid.]
[S01EC02, dichlorphenamide, The risk or severity of adverse effects can be increased when Thalidomide is combined with Diclofenamide.]
[S01BC03, diclofenac, The metabolism of Thalidomide can be decreased when combined with Diclofenac.]
[A03AA07, dicyclomine, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[G03CC02, dienestrol, Dienestrol may increase the thrombogenic activities of Thalidomide.]
[C02DG01, pinacidil, Thalidomide may increase the hypotensive activities of Pinacidil.]
[N05AD05, pipamperone, Pipamperone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[A03AB14, pipenzolate, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[L01DC04, ixabepilone, The risk or severity of adverse effects can be increased when Thalidomide is combined with Ixabepilone.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be increased when combined with Thalidomide.]
[L01DB08, pirarubicin, The risk or severity of adverse effects can be increased when Thalidomide is combined with Pirarubicin.]
[A08AA03, diethylpropion, Diethylpropion may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L02AA01, diethylstilbestrol, Diethylstilbestrol may increase the thrombogenic activities of Thalidomide.]
[C08CA03, isradipine, The risk or severity of adverse effects can be increased when Isradipine is combined with Thalidomide.]
[D07XC04, diflucortolone, The risk or severity of adverse effects can be increased when Thalidomide is combined with Difluocortolone.]
[A03AB11, poldine, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[C01AA04, digitoxin, Digitoxin may decrease the cardiotoxic activities of Thalidomide.]
[C01AA05, digoxin, Digoxin may decrease the cardiotoxic activities of Thalidomide.]
[C02DB01, dihydralazine, Thalidomide may increase the hypotensive activities of Dihydralazine.]
[L02AA02, polyestradiol phosphate, Polyestradiol phosphate may increase the thrombogenic activities of Thalidomide.]
[L01XX24, pegaspargase, The risk or severity of adverse effects can be increased when Pegaspargase is combined with Thalidomide.]
[N02CA01, dihydroergotamine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N02AA03, hydromorphone, Hydromorphone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L04AX04, lenalidomide, The risk or severity of adverse effects can be increased when Lenalidomide is combined with Thalidomide.]
[J05AE08, atazanavir, The metabolism of Thalidomide can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The metabolism of Thalidomide can be decreased when combined with Treprostinil.]
[D04AB07, pramoxine, Pramocaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C08DB01, diltiazem, The metabolism of Diltiazem can be increased when combined with Thalidomide.]
[R06AA11, dimenhydrinate, Dimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[M03BX03, pridinol, Pridinol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R06AB03, dimethindene, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[N03AG05, progabide, Progabide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[G03CA09, promestriene, Promestriene may increase the thrombogenic activities of Thalidomide.]
[C05CA03, diosmin, The metabolism of Thalidomide can be decreased when combined with Diosmin.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Thalidomide is combined with Proparacaine.]
[R06AA02, diphenhydramine, Diphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[A07DA01, diphenoxylate, Diphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05CD10, quazepam, Quazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C09AA06, quinapril, The risk or severity of adverse effects can be increased when Quinapril is combined with Thalidomide.]
[B01AC07, dipyridamole, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Thalidomide.]
[N06BA11, dexmethylphenidate, Dexmethylphenidate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[B01AD10, drotrecogin alfa, The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Thalidomide.]
[N06AA23, quinupramine, Quinupramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[A03FA02, cisapride, Cisapride may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C09AA05, ramipril, The risk or severity of adverse effects can be increased when Ramipril is combined with Thalidomide.]
[S01XA23, sirolimus, The risk or severity of adverse effects can be increased when Sirolimus is combined with Thalidomide.]
[N05AL04, remoxipride, Remoxipride may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C01BA03, disopyramide, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Thalidomide is combined with Natalizumab.]
[P03AA04, disulfiram, The risk or severity of peripheral neuropathy can be increased when Thalidomide is combined with Disulfiram.]
[S02AA12, rifamycin SV, The metabolism of Thalidomide can be decreased when combined with Rifamycin.]
[N07XX02, riluzole, Riluzole may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05AX08, risperidone, Risperidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R06AE09, levocetirizine, Levocetirizine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Efalizumab is combined with Thalidomide.]
[N01BB09, ropivacaine, Ropivacaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L01EX01, sunitinib, The risk or severity of adverse effects can be increased when Thalidomide is combined with Sunitinib.]
[A04AD12, aprepitant, The metabolism of Aprepitant can be increased when combined with Thalidomide.]
[L01XG01, bortezomib, The risk or severity of peripheral neuropathy can be increased when Thalidomide is combined with Bortezomib.]
[G04BE08, tadalafil, The metabolism of Tadalafil can be increased when combined with Thalidomide.]
[S01BC05, ketorolac, The metabolism of Thalidomide can be decreased when combined with Ketorolac.]
[C02KX02, ambrisentan, The metabolism of Ambrisentan can be increased when combined with Thalidomide.]
[R03AC12, salmeterol, The metabolism of Salmeterol can be increased when combined with Thalidomide.]
[A03FA03, domperidone, The metabolism of Domperidone can be increased when combined with Thalidomide.]
[N06AA16, dothiepin, Dosulepin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N06AA12, doxepin, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L01DB01, doxorubicin, The risk or severity of adverse effects can be increased when Doxorubicin is combined with Thalidomide.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N06AB06, sertraline, Sertraline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N01AB08, sevoflurane, Sevoflurane may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[A08AA10, sibutramine, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C10AA01, simvastatin, The metabolism of Simvastatin can be increased when combined with Thalidomide.]
[C09AA11, spirapril, Thalidomide may increase the hypotensive activities of Spirapril.]
[N05AL02, sultopride, Sultopride may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N02CC01, sumatriptan, Sumatriptan may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C07AB13, talinolol, Thalidomide may increase the hypotensive activities of Talinolol.]
[H01AA01, corticotropin, The risk or severity of adverse effects can be increased when Thalidomide is combined with Corticotropin.]
[L01AX03, temozolomide, The risk or severity of adverse effects can be increased when Temozolomide is combined with Thalidomide.]
[M01AC02, tenoxicam, The metabolism of Thalidomide can be decreased when combined with Tenoxicam.]
[G04CA03, terazosin, The risk or severity of adverse effects can be increased when Thalidomide is combined with Terazosin.]
[D01BA02, terbinafine, The metabolism of Thalidomide can be decreased when combined with Terbinafine.]
[M03BX07, tetrazepam, Tetrazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[M03BX05, thiocolchicoside, Thiocolchicoside may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05AB05, thiopropazate, Thiopropazate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[G04BD01, emepronium, Emepronium may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N06AX14, tianeptine, Tianeptine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[G03CX01, tibolone, Tibolone may increase the thrombogenic activities of Thalidomide.]
[C09AA02, enalapril, The risk or severity of adverse effects can be increased when Enalapril is combined with Thalidomide.]
[N05BA23, tofisopam, Tofisopam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N06AG03, toloxatone, Toloxatone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N03AX11, topiramate, Topiramate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C03CA04, torsemide, The metabolism of Thalidomide can be decreased when combined with Torasemide.]
[C09AA10, trandolapril, The risk or severity of adverse effects can be increased when Trandolapril is combined with Thalidomide.]
[N05CD11, triazulenone, Loprazolam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05CC01, chloral hydrate, Chloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05CM07, triclofos, Triclofos may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[A03AB08, tridihexethyl, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[B01AC18, triflusal, The risk or severity of bleeding can be increased when Triflusal is combined with Thalidomide.]
[H02CA01, trilostane, The risk or severity of adverse effects can be increased when Thalidomide is combined with Trilostane.]
[R06AA10, trimethobenzamide, Trimethobenzamide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L01AA07, trofosfamide, The risk or severity of adverse effects can be increased when Thalidomide is combined with Trofosfamide.]
[N04AA12, tropatepine, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[C05CA04, troxerutin, The risk or severity of bleeding can be increased when Troxerutin is combined with Thalidomide.]
[N01AB04, enflurane, Enflurane may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C02CA06, urapidil, Urapidil may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05AL06, veralipride, Veralipride may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L01CA04, vinorelbine, The risk or severity of adverse effects can be increased when Vinorelbine is combined with Thalidomide.]
[S01GX10, epinastine, Epinastine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N06AX16, venlafaxine, Venlafaxine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C08CA12, mepirodipine, The risk or severity of adverse effects can be increased when Thalidomide is combined with Barnidipine.]
[S01EA01, epinephrine, The metabolism of Thalidomide can be decreased when combined with Epinephrine.]
[L01DB03, epirubicin, The risk or severity of adverse effects can be increased when Epirubicin is combined with Thalidomide.]
[C09AA15, zofenopril, Thalidomide may increase the hypotensive activities of Zofenopril.]
[N05CF02, zolpidem, Zolpidem may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N03AX15, zonisamide, Zonisamide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05CF01, zopiclone, Zopiclone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05AX11, zotepine, Zotepine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[B01AD03, anistreplase, The risk or severity of bleeding can be increased when Anistreplase is combined with Thalidomide.]
[L01XA02, carboplatin, The risk or severity of adverse effects can be increased when Carboplatin is combined with Thalidomide.]
[C02AC02, guanfacine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[B01AC11, iloprost, The risk or severity of adverse effects can be increased when Thalidomide is combined with Iloprost.]
[C01BG01, moricizine, Moricizine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[G02AB03, ergonovine, Ergometrine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C04AE01, ergoloid mesylates, USP, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N02CA02, ergotamine, Ergotamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N03AG01, valproic acid, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[S01AA17, erythromycin, The metabolism of Erythromycin can be increased when combined with Thalidomide.]
[N05CD04, estazolam, Estazolam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[G03CA03, estradiol, Estradiol may increase the thrombogenic activities of Thalidomide.]
[L01XX11, estramustine, The risk or severity of adverse effects can be increased when Thalidomide is combined with Estramustine.]
[G03CC06, estriol, Estriol may increase the thrombogenic activities of Thalidomide.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may increase the thrombogenic activities of Thalidomide.]
[G03CC04, estrone, Estrone may increase the thrombogenic activities of Thalidomide.]
[J04AK02, ethambutol, The metabolism of Thalidomide can be decreased when combined with Ethambutol.]
[R03BA09, fluticasone furoate, The risk or severity of adverse effects can be increased when Thalidomide is combined with Fluticasone furoate.]
[R03BA05, fluticasone, The risk or severity of adverse effects can be increased when Thalidomide is combined with Fluticasone.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be increased when combined with Thalidomide.]
[N05CM08, ethchlorvynol, Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L02AA03, ethinyl estradiol, Ethinylestradiol may increase the thrombogenic activities of Thalidomide.]
[V03AF05, amifostine, The risk or severity of adverse effects can be increased when Thalidomide is combined with Amifostine.]
[N04AA05, profenamine, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Profenamine.]
[N03AD01, ethosuximide, Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N03AB01, ethotoin, Ethotoin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Thalidomide is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Thalidomide is combined with Meloxicam.]
[S01XA06, ethylmorphine, Ethylmorphine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Thalidomide is combined with Etidocaine.]
[N01AX07, etomidate, Etomidate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L01CB01, etoposide, The risk or severity of adverse effects can be increased when Etoposide is combined with Thalidomide.]
[N05AE03, sertindole, Sertindole may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L04AD02, tacrolimus, Tacrolimus may increase the immunosuppressive activities of Thalidomide.]
[R06AX11, astemizole, The metabolism of Astemizole can be increased when combined with Thalidomide.]
[R06AX12, terfenadine, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Terfenadine.]
[N06AX12, bupropion, Bupropion may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N06AB08, fluvoxamine, Fluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Muromonab is combined with Thalidomide.]
[B05AA05, dextran, The risk or severity of bleeding can be increased when Dextran is combined with Thalidomide.]
[M05BA01, etidronic acid, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Thalidomide is combined with Etidronic acid.]
[V03AF02, dexrazoxane, The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Thalidomide.]
[C08CA02, felodipine, The metabolism of Felodipine can be increased when combined with Thalidomide.]
[N03AX26, fenfluramine, Fenfluramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N02AB03, fentanyl, Fentanyl may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[B01AD05, plasmin, The risk or severity of bleeding can be increased when Fibrinolysin is combined with Thalidomide.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Thalidomide.]
[L04AA40, cladribine, The risk or severity of adverse effects can be increased when Cladribine is combined with Thalidomide.]
[G04BD02, flavoxate, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[C01BC04, flecainide, The metabolism of Thalidomide can be decreased when combined with Flecainide.]
[J02AC01, fluconazole, The metabolism of Thalidomide can be decreased when combined with Fluconazole.]
[J02AX01, flucytosine, The risk or severity of adverse effects can be increased when Thalidomide is combined with Flucytosine.]
[H02AA02, fludrocortisone, The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Thalidomide.]
[N07CA03, flunarizine, Flunarizine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05CD03, flunitrazepam, Flunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[D07AC08, fluocinonide, The risk or severity of adverse effects can be increased when Thalidomide is combined with Fluocinonide.]
[N06AA14, melitracen, Melitracen may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[H02AB03, fluocortolone, The risk or severity of adverse effects can be increased when Thalidomide is combined with Fluocortolone.]
[V03AZ01, ethanol, The risk or severity of somnolence and peripheral neuropathy can be increased when Thalidomide is combined with Ethanol.]
[L01BC09, floxuridine, The risk or severity of adverse effects can be increased when Floxuridine is combined with Thalidomide.]
[S01CB05, fluorometholone, The risk or severity of adverse effects can be increased when Fluorometholone is combined with Thalidomide.]
[L01BC02, fluorouracil, The risk or severity of adverse effects can be increased when Fluorouracil is combined with Thalidomide.]
[N06AB03, fluoxetine, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05AF01, flupenthixol, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05AB02, fluphenazine, Fluphenazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05CD01, flurazepam, Flurazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[S01BC04, flurbiprofen, The metabolism of Thalidomide can be decreased when combined with Flurbiprofen.]
[N05AG01, fluspirilene, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L02BB01, flutamide, The metabolism of Flutamide can be increased when combined with Thalidomide.]
[L01BC03, tegafur, The metabolism of Tegafur can be increased when combined with Thalidomide.]
[M03AA01, alcuronium, Alcuronium may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[G01AX06, furazolidone, Furazolidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C03CA01, furosemide, The risk or severity of adverse effects can be increased when Furosemide is combined with Thalidomide.]
[M05BA04, alendronic acid, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Thalidomide is combined with Alendronic acid.]
[N05CF04, eszopiclone, Eszopiclone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05AL05, amisulpride, Amisulpride may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[M03AC02, gallamine, Gallamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N03AA04, barbexaclone, Barbexaclone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N06AX08, bifemelane, Bifemelane may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C10AB04, gemfibrozil, The metabolism of Thalidomide can be decreased when combined with Gemfibrozil.]
[L01EA02, dasatinib, The risk or severity of adverse effects can be increased when Thalidomide is combined with Dasatinib.]
[N04BC06, cabergoline, Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[J05AG04, etravirine, The metabolism of Thalidomide can be decreased when combined with Etravirine.]
[N03AD03, methsuximide, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[G03XA02, gestrinone, Gestrinone may increase the thrombogenic activities of Thalidomide.]
[N01AH02, alfentanil, Alfentanil may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L01EH01, lapatinib, The metabolism of Lapatinib can be increased when combined with Thalidomide.]
[A10BB01, glyburide, The metabolism of Glyburide can be increased when combined with Thalidomide.]
[A10BB09, gliclazide, The metabolism of Gliclazide can be decreased when combined with Thalidomide.]
[A10BB07, glipizide, The metabolism of Glipizide can be decreased when combined with Thalidomide.]
[N05CM18, dexmedetomidine, Dexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05CE01, glutethimide, Glutethimide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C05AE01, nitroglycerin, The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Thalidomide.]
[C02CA04, doxazosin, The risk or severity of adverse effects can be increased when Doxazosin is combined with Thalidomide.]
[L01EX02, sorafenib, The risk or severity of adverse effects can be increased when Sorafenib is combined with Thalidomide.]
[C07AB09, esmolol, The risk or severity of adverse effects can be increased when Esmolol is combined with Thalidomide.]
[B01AA12, fluindione, The risk or severity of bleeding can be increased when Thalidomide is combined with Fluindione.]
[C09AA09, fosinopril, The risk or severity of adverse effects can be increased when Fosinopril is combined with Thalidomide.]
[S01EX01, guanethidine, Thalidomide may increase the hypotensive activities of Guanethidine.]
[P01BX01, halofantrine, The metabolism of Halofantrine can be increased when combined with Thalidomide.]
[N05AD01, haloperidol, Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N01AB01, halothane, Halothane may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05AH04, quetiapine, Quetiapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N02CX03, iprazochrome, Iprazochrome may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L01CE02, irinotecan, The risk or severity of adverse effects can be increased when Irinotecan is combined with Thalidomide.]
[N05CA21, allobarbital, Allobarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[M04AA01, allopurinol, The risk or severity of adverse effects can be increased when Allopurinol is combined with Thalidomide.]
[C09CA01, losartan, The risk or severity of adverse effects can be increased when Losartan is combined with Thalidomide.]
[S01XA14, heparin, The risk or severity of bleeding can be increased when Heparin is combined with Thalidomide.]
[L01XX03, altretamine, The risk or severity of adverse effects can be increased when Altretamine is combined with Thalidomide.]
[N05CA16, hexobarbital, Hexobarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[J05AG01, nevirapine, The metabolism of Nevirapine can be increased when combined with Thalidomide.]
[C08CA10, nilvadipine, The risk or severity of adverse effects can be increased when Thalidomide is combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of bleeding can be increased when Nimesulide is combined with Thalidomide.]
[C09AA04, perindopril, The risk or severity of adverse effects can be increased when Perindopril is combined with Thalidomide.]
[C02DB02, hydralazine, The risk or severity of adverse effects can be increased when Thalidomide is combined with Hydralazine.]
[C03AA03, hydrochlorothiazide, The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Thalidomide.]
[R05DA03, hydrocodone, Hydrocodone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[S02BA01, hydrocortisone, The metabolism of Hydrocortisone can be increased when combined with Thalidomide.]
[C03AA02, hydroflumethiazide, The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Thalidomide.]
[G04BD06, propiverine, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Propiverine.]
[P01BA02, hydroxychloroquine, The risk or severity of adverse effects can be increased when Thalidomide is combined with Hydroxychloroquine.]
[N05AX07, prothipendyl, Prothipendyl may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L01XX05, hydroxyurea, The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Thalidomide.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C02AC06, rilmenidine, Thalidomide may increase the hypotensive activities of Rilmenidine.]
[M05BA07, risedronic acid, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Thalidomide is combined with Risedronic acid.]
[R02AX02, ibuprofen, The metabolism of Ibuprofen can be decreased when combined with Thalidomide.]
[B05CB02, sodium citrate, The risk or severity of bleeding can be increased when Sodium citrate is combined with Thalidomide.]
[L01DB06, idarubicin, The risk or severity of adverse effects can be increased when Thalidomide is combined with Idarubicin.]
[L01AA06, ifosfamide, The risk or severity of adverse effects can be increased when Thalidomide is combined with Ifosfamide.]
[N01AH03, sufentanil, Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N06AA02, imipramine, Imipramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L01CD01, paclitaxel, The risk or severity of peripheral neuropathy can be increased when Thalidomide is combined with Paclitaxel.]
[L01CD03, paclitaxel poliglumex, The risk or severity of cardiotoxicity can be increased when Thalidomide is combined with Paclitaxel poliglumex.]
[R01AD07, tixocortol, The risk or severity of adverse effects can be increased when Thalidomide is combined with Tixocortol.]
[M03BX02, tizanidine, Tizanidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L01CE01, topotecan, The risk or severity of adverse effects can be increased when Topotecan is combined with Thalidomide.]
[C03BA11, indapamide, The risk or severity of adverse effects can be increased when Indapamide is combined with Thalidomide.]
[S01BC01, indomethacin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Thalidomide.]
[C02CA02, indoramin, The risk or severity of adverse effects can be increased when Thalidomide is combined with Indoramin.]
[L03AB04, interferon alfa-2a, The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Thalidomide.]
[L03AB05, interferon alfa-2b, The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Thalidomide.]
[N06AX17, milnacipran, Milnacipran may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[A03AA30, piperidolate, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Thalidomide is combined with Eculizumab.]
[N01BB08, articaine, Articaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05BA12, alprazolam, Alprazolam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05CH02, ramelteon, Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R06AE01, buclizine, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[C10AA06, cerivastatin, The metabolism of Cerivastatin can be increased when combined with Thalidomide.]
[L01XX35, anagrelide, The risk or severity of bleeding can be increased when Anagrelide is combined with Thalidomide.]
[C07AA01, alprenolol, Alprenolol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L03AB09, interferon alfacon-1, The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Thalidomide.]
[N06AA13, iprindole, Iprindole may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N06AF05, iproniazid, Iproniazid may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05AA07, chlorproethazine, Chlorproethazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[P01AX06, atovaquone, The metabolism of Thalidomide can be decreased when combined with Atovaquone.]
[C09AA16, imidapril, The risk or severity of adverse effects can be increased when Thalidomide is combined with Imidapril.]
[N01AB06, isoflurane, Isoflurane may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N04BX02, entacapone, Entacapone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[J04AC01, isoniazid, The metabolism of Thalidomide can be decreased when combined with Isoniazid.]
[C01DA14, isosorbide mononitrate, The risk or severity of adverse effects can be increased when Isosorbide mononitrate is combined with Thalidomide.]
[C05AE02, isosorbide dinitrate, The risk or severity of adverse effects can be increased when Isosorbide dinitrate is combined with Thalidomide.]
[C04AA01, isoxsuprine, The risk or severity of adverse effects can be increased when Thalidomide is combined with Isoxsuprine.]
[B01AE06, bivalirudin, The risk or severity of bleeding can be increased when Bivalirudin is combined with Thalidomide.]
[N06AX18, reboxetine, Reboxetine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L04AC07, tocilizumab, The metabolism of Thalidomide can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, Ketamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C02KD01, ketanserin, Ketanserin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[B01AC22, prasugrel, The risk or severity of bleeding can be increased when Prasugrel is combined with Thalidomide.]
[N05AH03, olanzapine, Olanzapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L04AA24, abatacept, The metabolism of Thalidomide can be increased when combined with Abatacept.]
[N04BC09, rotigotine, Rotigotine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C07AG01, labetalol, The risk or severity of adverse effects can be increased when Labetalol is combined with Thalidomide.]
[C02AA05, deserpidine, Thalidomide may increase the hypotensive activities of Deserpidine.]
[A06AD11, lactulose, The therapeutic efficacy of Lactulose can be decreased when used in combination with Thalidomide.]
[N03AX18, lacosamide, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C03CC01, ethacrynic acid, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Thalidomide.]
[L01DC03, mitomycin, The risk or severity of adverse effects can be increased when Mitomycin is combined with Thalidomide.]
[G03AD01, levonorgestrel, Levonorgestrel may increase the thrombogenic activities of Thalidomide.]
[N04BA01, levodopa, Levodopa may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[S02DA01, lidocaine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N06BA13, armodafinil, The metabolism of Thalidomide can be decreased when combined with Armodafinil.]
[C03DB01, amiloride, The risk or severity of adverse effects can be increased when Amiloride is combined with Thalidomide.]
[N02CA07, lisuride, Lisuride may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N06AA07, lofepramine, Lofepramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L01AD02, lomustine, The risk or severity of adverse effects can be increased when Thalidomide is combined with Lomustine.]
[N05BA06, lorazepam, Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C10AA02, lovastatin, The metabolism of Lovastatin can be increased when combined with Thalidomide.]
[N05AH01, loxapine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[G03DC03, lynestrenol, Lynestrenol may increase the thrombogenic activities of Thalidomide.]
[L01EG01, temsirolimus, The risk or severity of adverse effects can be increased when Thalidomide is combined with Temsirolimus.]
[V04CC02, magnesium sulfate, Magnesium sulfate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L01BA05, pralatrexate, The risk or severity of adverse effects can be increased when Thalidomide is combined with Pralatrexate.]
[L01EA03, nilotinib, The risk or severity of adverse effects can be increased when Thalidomide is combined with Nilotinib.]
[V04CX04, mannitol, The risk or severity of adverse effects can be increased when Mannitol is combined with Thalidomide.]
[N06AA21, maprotiline, Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[A08AA05, mazindol, Mazindol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C02BB01, mecamylamine, The risk or severity of adverse effects can be increased when Mecamylamine is combined with Thalidomide.]
[L01AA05, mechlorethamine, The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Thalidomide.]
[R06AE05, meclizine, Meclizine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05BA03, medazepam, Medazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C01AA08, medigoxin, Metildigoxin may decrease the cardiotoxic activities of Thalidomide.]
[B01AB06, nadroparin, The risk or severity of bleeding can be increased when Nadroparin is combined with Thalidomide.]
[B01AB05, enoxaparin, The risk or severity of bleeding can be increased when Enoxaparin is combined with Thalidomide.]
[B01AB04, dalteparin, The risk or severity of bleeding can be increased when Dalteparin is combined with Thalidomide.]
[N05CH01, melatonin, Melatonin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L01AA03, melphalan, The risk or severity of adverse effects can be increased when Thalidomide is combined with Melphalan.]
[N02AB02, meperidine, Meperidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N03AB04, mephenytoin, Mephenytoin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N03AA01, mephobarbital, Methylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N01BB03, mepivacaine, Mepivacaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05BC01, meprobamate, Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N02AX05, meptazinol, Meptazinol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05AC03, mesoridazine, Mesoridazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05AX13, paliperidone, Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[A04AA04, dolasetron, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N07BC02, methadone, Methadone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N06BA03, methamphetamine, Metamfetamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[A03AB07, methantheline, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, Methapyrilene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05CM01, methaqualone, Methaqualone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N03AA30, metharbital, Metharbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[S01EC05, methazolamide, The risk or severity of adverse effects can be increased when Methazolamide is combined with Thalidomide.]
[G02CB05, metergoline, Metergoline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[H03BB02, methimazole, The risk or severity of adverse effects can be increased when Methimazole is combined with Thalidomide.]
[L01BA04, pemetrexed, The risk or severity of adverse effects can be increased when Pemetrexed is combined with Thalidomide.]
[M03BA03, methocarbamol, Methocarbamol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05CA15, methohexital, Methohexital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N02BG08, ziconotide, Ziconotide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L04AX03, methotrexate, The risk or severity of adverse effects can be increased when Methotrexate is combined with Thalidomide.]
[N05AA02, methotrimeprazine, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N02BG09, methoxyflurane, Methoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C03AA08, methyclothiazide, The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Thalidomide.]
[C02AB01, methyldopa, The risk or severity of adverse effects can be increased when Methyldopa is combined with Thalidomide.]
[V04CG05, methylene blue, Methylene blue may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[H02AB04, methylprednisolone, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Thalidomide.]
[N03AF03, rufinamide, Rufinamide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05CE02, methyprylon, Methyprylon may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N02CA04, methysergide, Methysergide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[A03FA01, metoclopramide, The risk or severity of sedation can be increased when Metoclopramide is combined with Thalidomide.]
[C03BA08, metolazone, The risk or severity of adverse effects can be increased when Metolazone is combined with Thalidomide.]
[C07AB02, metoprolol, The risk or severity of adverse effects can be increased when Metoprolol is combined with Thalidomide.]
[P01AB01, metronidazole, The risk or severity of peripheral neuropathy can be increased when Thalidomide is combined with Metronidazole.]
[N06AX03, mianserin, Mianserin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[S02AA13, miconazole, The metabolism of Thalidomide can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be decreased when combined with Thalidomide.]
[B01AB07, parnaparin, The risk or severity of bleeding can be increased when Parnaparin is combined with Thalidomide.]
[N05CD08, midazolam, Midazolam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[G03XB01, mifepristone, Mifepristone may increase the thrombogenic activities of Thalidomide.]
[B01AB10, tinzaparin, The risk or severity of bleeding can be increased when Tinzaparin is combined with Thalidomide.]
[C09CA03, valsartan, The metabolism of Thalidomide can be decreased when combined with Valsartan.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[D11AX01, minoxidil, The risk or severity of adverse effects can be increased when Minoxidil is combined with Thalidomide.]
[L01DB07, mitoxantrone, The risk or severity of adverse effects can be increased when Thalidomide is combined with Mitoxantrone.]
[N05AE02, molindone, Molindone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Thalidomide.]
[C01BD01, amiodarone, The risk or severity of peripheral neuropathy can be increased when Thalidomide is combined with Amiodarone.]
[N06AA09, amitriptyline, Amitriptyline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N02AA01, morphine, Morphine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[A04AA05, palonosetron, Palonosetron may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L04AB05, certolizumab pegol, The metabolism of Thalidomide can be increased when combined with Certolizumab pegol.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Thalidomide is combined with Ofatumumab.]
[L01EX03, pazopanib, The risk or severity of adverse effects can be increased when Thalidomide is combined with Pazopanib.]
[L04AA06, mycophenolic acid, The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Thalidomide.]
[M03AC03, vecuronium, Vecuronium may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05CA02, amobarbital, Amobarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[P01BA06, amodiaquine, The metabolism of Thalidomide can be decreased when combined with Amodiaquine.]
[R03BB01, ipratropium bromide, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA17, amoxapine, Amoxapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N03AB05, fosphenytoin, Fosphenytoin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L03AB08, interferon beta-1b, The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Thalidomide.]
[C07AA12, nadolol, The risk or severity of adverse effects can be increased when Thalidomide is combined with Nadolol.]
[N04BC04, ropinirole, Thalidomide may increase the sedative activities of Ropinirole.]
[C04AX21, nafronyl, Naftidrofuryl may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N02AF02, nalbuphine, Nalbuphine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L04AC03, anakinra, The metabolism of Thalidomide can be increased when combined with Anakinra.]
[M02AA12, naproxen, The metabolism of Thalidomide can be decreased when combined with Naproxen.]
[A10BG01, troglitazone, The metabolism of Thalidomide can be decreased when combined with Troglitazone.]
[N06AX21, duloxetine, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N04BX01, tolcapone, Tolcapone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of thromboembolism can be increased when Thalidomide is combined with Methoxy polyethylene glycol-epoetin beta.]
[L01CD02, docetaxel, The risk or severity of peripheral neuropathy can be increased when Thalidomide is combined with Docetaxel.]
[N01AH06, remifentanil, Remifentanil may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C01CX08, levosimendan, The risk or severity of adverse effects can be increased when Levosimendan is combined with Thalidomide.]
[B01AC17, tirofiban, The risk or severity of bleeding can be increased when Tirofiban is combined with Thalidomide.]
[N05AX14, iloperidone, Iloperidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[J02AA01, amphotericin B, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Thalidomide.]
[N06AX23, desvenlafaxine, Desvenlafaxine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C09CA07, telmisartan, The risk or severity of adverse effects can be increased when Telmisartan is combined with Thalidomide.]
[L01XX01, amsacrine, The risk or severity of adverse effects can be increased when Amsacrine is combined with Thalidomide.]
[N06AF02, nialamide, Nialamide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C08CA04, nicardipine, The metabolism of Thalidomide can be decreased when combined with Nicardipine.]
[P02DA01, niclosamide, The metabolism of Niclosamide can be decreased when combined with Thalidomide.]
[C08CA05, nifedipine, The metabolism of Nifedipine can be increased when combined with Thalidomide.]
[V03AB22, amyl nitrite, The risk or severity of adverse effects can be increased when Thalidomide is combined with Amyl Nitrite.]
[C08CA06, nimodipine, The risk or severity of adverse effects can be increased when Nimodipine is combined with Thalidomide.]
[C08CA07, nisoldipine, The metabolism of Nisoldipine can be increased when combined with Thalidomide.]
[N05CD02, nitrazepam, Nitrazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C08CA08, nitrendipine, The metabolism of Nitrendipine can be increased when combined with Thalidomide.]
[R07AX01, nitric oxide, The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Thalidomide.]
[N05CF03, zaleplon, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N04BC05, pramipexole, Thalidomide may increase the sedative activities of Pramipexole.]
[C02DD01, nitroprusside, The risk or severity of adverse effects can be increased when Nitroprusside is combined with Thalidomide.]
[N01AX13, nitrous oxide, Nitrous oxide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N06AX04, nomifensine, Nomifensine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[G03DC02, norethindrone, Norethisterone may increase the thrombogenic activities of Thalidomide.]
[G03AC07, norgestrienone, Norgestrienone may increase the thrombogenic activities of Thalidomide.]
[C02KX01, bosentan, The metabolism of Thalidomide can be increased when combined with Bosentan.]
[N06AA10, nortriptyline, Nortriptyline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R05DA07, noscapine, The metabolism of Thalidomide can be decreased when combined with Noscapine.]
[B01AC16, eptifibatide, The risk or severity of bleeding can be increased when Eptifibatide is combined with Thalidomide.]
[B01AB08, reviparin, The risk or severity of bleeding can be increased when Reviparin is combined with Thalidomide.]
[L04AC04, rilonacept, The metabolism of Thalidomide can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Thalidomide can be decreased when combined with Omeprazole.]
[N06AA05, opipramol, Opipramol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N02AA02, opium, Opium may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[B01AD07, reteplase, The risk or severity of bleeding can be increased when Reteplase is combined with Thalidomide.]
[B01AD09, ancrod, The risk or severity of bleeding can be increased when Ancrod is combined with Thalidomide.]
[G04CA02, tamsulosin, The risk or severity of adverse effects can be increased when Tamsulosin is combined with Thalidomide.]
[C01AC01, ouabain, Ouabain may decrease the cardiotoxic activities of Thalidomide.]
[M05BA08, zoledronic acid, The risk or severity of jaw osteonecrosis can be increased when Thalidomide is combined with Zoledronic acid.]
[A14AA08, oxandrolone, The metabolism of Thalidomide can be decreased when combined with Oxandrolone.]
[N05BA04, oxazepam, Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C07AA02, oxprenolol, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N02AA05, oxycodone, Oxycodone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N02AA11, oxymorphone, Oxymorphone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05AE01, oxypertine, Oxypertine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[A03AB03, oxyphenonium, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[N05AH05, asenapine, Asenapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[B01AB09, danaparoid, The risk or severity of bleeding can be increased when Danaparoid is combined with Thalidomide.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[M03AC01, pancuronium, Pancuronium may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[G03DB06, chlormadinone, Chlormadinone may increase the thrombogenic activities of Thalidomide.]
[G04BE02, papaverine, The risk or severity of adverse effects can be increased when Thalidomide is combined with Papaverine.]
[N05CC05, paraldehyde, Paraldehyde may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[H02AB05, paramethasone, The risk or severity of adverse effects can be increased when Thalidomide is combined with Paramethasone.]
[C02KC01, pargyline, Pargyline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[G04BD11, fesoterodine, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, Penbutolol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05AG03, penfluridol, Penfluridol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[M01CC01, penicillamine, The risk or severity of adverse effects can be increased when Penicillamine is combined with Thalidomide.]
[J07AF01, diphtheria toxoid vaccine, inactivated, The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Thalidomide.]
[J07AM01, tetanus toxoid vaccine, inactivated, The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Thalidomide.]
[N02AD01, pentazocine, Pentazocine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05CA01, pentobarbital, Pentobarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L01XX08, pentostatin, The risk or severity of adverse effects can be increased when Pentostatin is combined with Thalidomide.]
[C04AD03, pentoxifylline, The risk or severity of bleeding can be increased when Pentoxifylline is combined with Thalidomide.]
[N05AB10, perazine, Perazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N04BC02, pergolide, Pergolide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05AB03, perphenazine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[J07AJ, pertussis vaccine, The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Thalidomide.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Thalidomide.]
[N02AD02, phenazocine, Phenazocine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N06AF03, phenelzine, Phenelzine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[B01AA02, phenindione, The risk or severity of bleeding can be increased when Thalidomide is combined with Phenindione.]
[N03AA02, phenobarbital, Phenobarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N01AH04, phenoperidine, Phenoperidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C04AX02, phenoxybenzamine, The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Thalidomide.]
[B01AA04, phenprocoumon, The risk or severity of bleeding can be increased when Thalidomide is combined with Phenprocoumon.]
[V03AB36, phentolamine, The risk or severity of adverse effects can be increased when Phentolamine is combined with Thalidomide.]
[M02AA01, phenylbutazone, The metabolism of Thalidomide can be decreased when combined with Phenylbutazone.]
[N03AB02, phenytoin, The risk or severity of somnolence and peripheral neuropathy can be increased when Thalidomide is combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Thalidomide can be increased when combined with Golimumab.]
[C08CX01, mibefradil, Thalidomide may increase the hypotensive activities of Mibefradil.]
[N05AG02, pimozide, Pimozide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C07AA03, pindolol, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be increased when combined with Thalidomide.]
[J05AE01, saquinavir, The metabolism of Saquinavir can be increased when combined with Thalidomide.]
[N05AC04, pipothiazine, Pipotiazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C09CA02, eprosartan, The risk or severity of adverse effects can be increased when Eprosartan is combined with Thalidomide.]
[A02BX03, pirenzepine, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N02AC03, pirinitramide, Piritramide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[S01BC06, piroxicam, The metabolism of Thalidomide can be decreased when combined with Piroxicam.]
[N02CX01, pizotyline, Pizotifen may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[J05AG02, delavirdine, The metabolism of Thalidomide can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The risk or severity of adverse effects can be increased when Irbesartan is combined with Thalidomide.]
[N05CA22, proxibarbal, Proxibarbal may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[B01AC13, abciximab, The risk or severity of bleeding can be increased when Abciximab is combined with Thalidomide.]
[S01XA13, alteplase, The risk or severity of bleeding can be increased when Alteplase is combined with Thalidomide.]
[A10BG02, rosiglitazone, The metabolism of Thalidomide can be decreased when combined with Rosiglitazone.]
[L02BG03, anastrozole, The risk or severity of cardiotoxicity can be increased when Thalidomide is combined with Anastrozole.]
[A03AE01, alosetron, Alosetron may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L04AC08, canakinumab, The metabolism of Thalidomide can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Thalidomide.]
[J05AE03, ritonavir, The metabolism of Ritonavir can be increased when combined with Thalidomide.]
[A10BH03, saxagliptin, The metabolism of Saxagliptin can be increased when combined with Thalidomide.]
[C10AA08, pitavastatin, The metabolism of Pitavastatin can be decreased when combined with Thalidomide.]
[C07AB01, practolol, Thalidomide may increase the hypotensive activities of Practolol.]
[N05BA11, prazepam, Prazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be increased when combined with Thalidomide.]
[C02CA01, prazosin, The risk or severity of adverse effects can be increased when Prazosin is combined with Thalidomide.]
[S03BA02, prednisolone, The risk or severity of adverse effects can be increased when Prednisolone is combined with Thalidomide.]
[H02AB07, prednisone, The risk or severity of adverse effects can be increased when Prednisone is combined with Thalidomide.]
[N01BB04, prilocaine, Prilocaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N03AA03, primidone, Primidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[M04AB01, probenecid, The metabolism of Thalidomide can be decreased when combined with Probenecid.]
[S01HA05, procaine, Procaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L01XB01, procarbazine, Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C10AB05, fenofibrate, The metabolism of Thalidomide can be decreased when combined with Fenofibrate.]
[N05AB04, prochlorperazine, Prochlorperazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N04AA04, procyclidine, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[G03DA04, progesterone, Progesterone may increase the thrombogenic activities of Thalidomide.]
[N05AA03, promazine, Promazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R06AD02, promethazine, Promethazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N01AX04, propanidid, Propanidid may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[A03AB05, propantheline, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, Periciazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05CM06, propiomazine, Propiomazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be increased when combined with Thalidomide.]
[N01AX10, propofol, Propofol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N02AC04, propoxyphene, Dextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C07AA05, propranolol, The serum concentration of Propranolol can be increased when it is combined with Thalidomide.]
[H03BA02, propylthiouracil, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Thalidomide.]
[C01AB01, proscillaridin, Proscillaridin may decrease the cardiotoxic activities of Thalidomide.]
[N02CC04, rizatriptan, Rizatriptan may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[B01AC09, epoprostenol, The risk or severity of adverse effects can be increased when Thalidomide is combined with Epoprostenol.]
[R03DC03, montelukast, The metabolism of Thalidomide can be decreased when combined with Montelukast.]
[N06AA11, protriptyline, Protriptyline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05AX12, aripiprazole, Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[A03AB15, diphemanil, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, Talbutal may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05CA09, vinbarbital, Vinbarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05BB02, captodiamine, Captodiame may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[M03BA04, styramate, Styramate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[P02CC01, pyrantel, Pyrantel may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[J06BB05, rabies immune globulin, human, The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Thalidomide.]
[R06AC01, pyrilamine, Mepyramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[P01AX05, quinacrine, The metabolism of Quinacrine can be increased when combined with Thalidomide.]
[C01BA01, quinidine, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Quinidine.]
[P01BC01, quinine, Quinine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[C02AA01, rescinnamine, Thalidomide may increase the hypotensive activities of Rescinnamine.]
[C02AA02, reserpine, Reserpine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N06AX01, 5-hydroxytryptophan, Oxitriptan may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[A07EC01, sulfasalazine, The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Thalidomide.]
[S01BC08, salicylic acid, The metabolism of Thalidomide can be decreased when combined with Salicylic acid.]
[S01FA02, scopolamine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N05CA06, secobarbital, Secobarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[N04BD01, selegiline, Selegiline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Thalidomide is combined with Obinutuzumab.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Thalidomide.]
[C07AA07, sotalol, The risk or severity of adverse effects can be increased when Sotalol is combined with Thalidomide.]
[L01CD04, cabazitaxel, The risk or severity of adverse effects can be increased when Thalidomide is combined with Cabazitaxel.]
[L03AX17, sipuleucel-T, The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Thalidomide.]
[C03DA01, spironolactone, The risk or severity of adverse effects can be increased when Spironolactone is combined with Thalidomide.]
[D07AB02, hydrocortisone butyrate, The risk or severity of adverse effects can be increased when Thalidomide is combined with Hydrocortisone butyrate.]
